# ORIC Pharmaceuticals (ORIC) — Analyst Forecast

ORIC · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/oric/forecast

## Analyst consensus

| Consensus | Buy | Hold | Sell | Analysts |
| --- | --- | --- | --- | --- |
| Buy | 14 | 1 | 0 | 15 |

## Price target

| Low | Average | High | Analysts |
| --- | --- | --- | --- |
| $26.00 | $26.25 | $27.00 | 4 |

Last price $12.77 (as of Oct 16, 2026).

## Recent analyst ratings

| Date | Firm | Action | Rating | Price target |
| --- | --- | --- | --- | --- |
| Oct 14, 2026 | JP Morgan | Maintained | Overweight | $26.00 |
| Oct 5, 2026 | Leerink Partners | Initiated Coverage | Outperform | $26.00 |
| Sep 23, 2026 | BTIG | Initiated Coverage | Buy | $26.00 |
| Aug 10, 2026 | HC Wainwright & Co. | Maintained | Buy | $27.00 |
| Jun 8, 2026 | HC Wainwright & Co. | Maintained | Buy | $25.00 |
| May 5, 2026 | Citigroup | Maintained | Buy | $16.00 |
| Apr 2, 2026 | HC Wainwright & Co. | Maintained | Buy | $25.00 |
| Apr 1, 2026 | Wedbush | Maintained | Outperform | $17.00 |
| Mar 13, 2026 | HC Wainwright & Co. | Maintained | Buy | $25.00 |
| Feb 24, 2026 | Wedbush | Maintained | Outperform | $20.00 |
| Feb 24, 2026 | HC Wainwright & Co. | Maintained | Buy | $25.00 |
| Feb 24, 2026 | Citigroup | Maintained | Buy | $17.00 |
| Jan 13, 2026 | Wedbush | Maintained | Outperform | $20.00 |
| Jan 7, 2026 | Piper Sandler | Initiated Coverage | Overweight | $22.00 |
| Dec 8, 2025 | Wedbush | Maintained | Outperform | $20.00 |
| Dec 8, 2025 | Wells Fargo | Maintained | Overweight | $25.00 |
| Nov 20, 2025 | Evercore ISI Group | Initiated Coverage | Outperform | $25.00 |
| Nov 18, 2025 | JP Morgan | Maintained | Overweight | $20.00 |
| Nov 18, 2025 | Wolfe Research | Initiated Coverage | Peer Perform | — |
| Nov 17, 2025 | Citigroup | Maintained | Buy | $16.00 |

## Frequently Asked Questions

### What is the price target for ORIC stock?

The average 12-month analyst price target for ORIC Pharmaceuticals (ORIC) is $26.25, with a high estimate of $27.00 and a low of $26.00, across 4 analysts.

### Is ORIC a buy, sell, or hold?

Analysts covering ORIC Pharmaceuticals currently average a Buy rating: 14 buy, 1 hold and 0 sell, from 15 analysts. Ratings reflect analyst opinion, not investment advice.

### What upside do analysts see for ORIC?

The average price target of $26.25 implies 105.56% upside from the last price of $12.77.

### What is the latest analyst rating on ORIC?

On Oct 14, 2026, JP Morgan maintained ORIC Pharmaceuticals at Overweight with a price target of $26.00.

---

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).